Skip to main content
Journal cover image

MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.

Publication ,  Journal Article
Fealey, ME; Scheithauer, BW; Horvath, E; Erickson, D; Kovacs, K; McLendon, R; Lloyd, RV
Published in: Endocr Pathol
September 2010

The objective of the study was to assess O(6)-methylguanine-DNA methyltransferase (MGMT) immunoreactivity in pituitary adenomas of silent subtype 3 as a potential indicator of temozolomide susceptibility. The Mayo Clinic Anatomic Pathology Database was searched for all cases of silent subtype 3 pituitary adenoma. Each of the 23 cases identified had been confirmed on the basis of histology, immunohistochemical staining for pituitary hormones, as well as on diagnostic ultrastructural criteria. Unstained microscopic sections were immunostained for MGMT and were semiquantitatively assessed. Of the 23 tumors examined, 18 (78%) showed no MGMT immunoreactivity. The remaining five (22%) showed immunoreactivity in < or =50% of tumor cells. Among eight of the most clinically aggressive tumors in this study, six (75%) lacked MGMT immunoreactivity. The observed lack of or low-level expression of MGMT by this distinctive, clinically aggressive form of pituitary adenoma suggests potential efficacy of treatment with the alkylating agent temozolomide.

Duke Scholars

Published In

Endocr Pathol

DOI

EISSN

1559-0097

Publication Date

September 2010

Volume

21

Issue

3

Start / End Page

161 / 165

Location

United States

Related Subject Headings

  • Young Adult
  • Tumor Suppressor Proteins
  • Temozolomide
  • Promoter Regions, Genetic
  • Pituitary Neoplasms
  • Pathology
  • Middle Aged
  • Male
  • Immunohistochemistry
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fealey, M. E., Scheithauer, B. W., Horvath, E., Erickson, D., Kovacs, K., McLendon, R., & Lloyd, R. V. (2010). MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. Endocr Pathol, 21(3), 161–165. https://doi.org/10.1007/s12022-010-9120-0
Fealey, Michael E., Bernd W. Scheithauer, Eva Horvath, Dana Erickson, Kalman Kovacs, Roger McLendon, and Ricardo V. Lloyd. “MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.Endocr Pathol 21, no. 3 (September 2010): 161–65. https://doi.org/10.1007/s12022-010-9120-0.
Fealey ME, Scheithauer BW, Horvath E, Erickson D, Kovacs K, McLendon R, et al. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. Endocr Pathol. 2010 Sep;21(3):161–5.
Fealey, Michael E., et al. “MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.Endocr Pathol, vol. 21, no. 3, Sept. 2010, pp. 161–65. Pubmed, doi:10.1007/s12022-010-9120-0.
Fealey ME, Scheithauer BW, Horvath E, Erickson D, Kovacs K, McLendon R, Lloyd RV. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. Endocr Pathol. 2010 Sep;21(3):161–165.
Journal cover image

Published In

Endocr Pathol

DOI

EISSN

1559-0097

Publication Date

September 2010

Volume

21

Issue

3

Start / End Page

161 / 165

Location

United States

Related Subject Headings

  • Young Adult
  • Tumor Suppressor Proteins
  • Temozolomide
  • Promoter Regions, Genetic
  • Pituitary Neoplasms
  • Pathology
  • Middle Aged
  • Male
  • Immunohistochemistry
  • Humans